PREVIOUS
✖
CDSCO – Qartemi
January 29 , 2025
2 days
67
0
- Bengaluru-based biotech startup, has launched Qartemi, a CAR-T cell therapy for patients with B-cell Non-Hodgkin Lymphoma (B-NHL).
- This "living drug" has been approved for blood cancer patients in India who suffer from an advanced or relapsed stage of the disease.
- This is different from a traditional chemical drug, made from cells to have a long-lasting immune response.
- India faces around 1,20,000 new cases and over 70,000 deaths annually from leukemia, lymphoma, and multiple myeloma.
Leave a Reply
Your Comment is awaiting moderation.